Tissue plasminogen activator and neuroserpin are widely expressed in the human central nervous system

Summary

Tissue plasminogen activator (tPA) is increasingly recognized to play important roles in various physiological and pathological processes in the central nervous system (CNS). Much of the data on the involvement of plasminogen activators in neurophysiology and -pathology have been derived from studies on experimental animals. We have now performed a systematic characterization of the expression of tPA and its inhibitor, neuroserpin, in normal human CNS. Brain and spinal cord samples from 30-36 anatomic locations covering all major brain regions were collected at 9 autopsies of donors with no neurological disease. Tissues were embedded in paraffin and tissue arrays were constructed. In two cases parallel samples were snap-frozen for biochemical analysis. Expression and activity profiling of tPA and neuroserpin were performed by immunohistochemistry, in situ hybridization, immunocapture and zymography assays. In the adult CNS, tPA was expressed at the mRNA and protein levels in many types of neurons, in particular in thalamus, cortex of cerebellum, pontine nuclei, neocortex, limbic system, and medulla oblongata. Interestingly, tPA was often co-expressed with its CNS inhibitor, neuroserpin. Despite overlapping expression of tPA and neuroserpin, zymography and immunocapture assays demonstrated that human neural tissue is a rich source of active tPA. Our analysis documents a detailed map of expression of tPA and its inhibitor in the human CNS and is compatible with the view that tPA is a key player in CNS physiology and pathology.

Keywords

Tissue plasminogen activator - neuroserpin - human central nervous system - neuron - tissue array

• References

• 1 Collen D. Ham-Wasserman lecture: role of the plasminogen system in fibrin-homeostasis and tissue remodeling. Hematology (Am Soc Hematol Educ Program) 2001; 1-9.
• 2 Nieuwenhuizen W. Fibrin-mediated plasminogen activation. Ann N Y Acad Sci 2001; 936: 237-246.
• 3 Kooistra T, Schrauwen Y, Arts J. et al. Regulation of endothelial cell t-PA synthesis and release. Int J Hematol 1994; 59: 233-255.
• 4 Sappino AP, Madani R, Huarte J. et al. Extracellular proteolysis in the adult murine brain. J Clin Invest 1993; 92: 679-685.
• 5 Friedman GC, Seeds NW. Tissue plasminogen activator expression in the embryonic nervous system. Brain Res Dev Brain Res 1994; 81: 41-49.
• 6 Seeds NW, Basham ME, Haffke SP. Neuronal migration is retarded in mice lacking the tissue plasminogen activator gene. Proc Natl Acad Sci U S A 1999; 96: 14118-23.
• 7 Qian Z, Gilbert ME, Colicos MA. et al. Tissue-plasminogen activator is induced as an immediate-early gene during seizure, kindling and long-term potentiation. Nature 1993; 361: 453-457.
• 8 Muller CM, Griesinger CB. Tissue plasminogen activator mediates reverse occlusion plasticity in visual cortex. Nat Neurosci 1998; 01: 47-53.
• 9 Strickland S. Tissue plasminogen activator in nervous system function and dysfunction. Thromb Haemost 2001; 86: 138-143.
• 10 Hastings GA, Coleman TA, Haudenschild CC. et al. Neuroserpin, a brain-associated inhibitor of tissue plasminogen activator is localized primarily in neurons. Implications for the regulation of motor learning and neuronal survival. J Biol Chem 1997; 272: 33062-7.
• 11 Krueger SR, Ghisu GP, Cinelli P. et al. Expression of neuroserpin, an inhibitor of tissue plasminogen activator, in the developing and adult nervous system of the mouse. J Neurosci 1997; 17: 8984-8996.
• 12 Yepes M, Lawrence DA. Neuroserpin: a selective inhibitor of tissue-type plasminogen activator in the central nervous system. Thromb Haemost 2004; 09: 457-464.
• 13 Salles FJ, Strickland S. Localization and regulation of the tissue plasminogen activatorplasmin system in the hippocampus. J Neurosci 2002; 22: 2125-2134.
• 14 Enard W, Khaitovich P, Klose J. et al. Intraand interspecific variation in primate gene expression patterns. Science 2002; 296: 340-343.
• 15 Kononen J, Bubendorf L, Kallioniemi A. et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens. Nat Med 1998; 04: 844-847.
• 16 Teesalu T, Blasi F, Talarico D. Embryo implantation in mouse: fetomaternal coordination in the pattern of expression of uPA, uPAR, PAI-1 and alpha 2MR/LRP genes. Mech Dev 1996; 56: 103-116.
• 17 Akenami FOT, Sirén V, Wessman M. et al. Tissue plasminogen activator gene expression in multiple sclerosis brain tissue. J Neurol Sci 1999; 165: 71-76.
• 18 Behrendtsen O, Alexander CM, Werb Z. Metalloproteinases mediate extracellular matrix degradation by cells from mouse blastocyst outgrowths. Development 1992; 114: 447-456.
• 19 Stephens R, Leung KC, Pollanen J. et al. Microplate immunocapture assay for plasminogen activators and their specific inhibitors. J Immunol Methods 1987; 105: 245-251.
• 20 Teesalu T, Kulla A, Asser T. et al. Tissue plasminogen activator as a key effector in neurobiology and neuropathology. Biochem Soc Trans 2002; 30: 183-189.
• 21 Menashi S, Lu H, Soria C, Legrand Y. Endothelial cell proteases: physiological role and regulation. Baillieres Clin Haematol 1993; 06: 559-576.
• 22 Renatus M, Engh RA, Stubbs MT. et al. Lysine 156 promotes the anomalous proenzyme activity of tPA: X-ray crystal structure of single-chain human tPA. EMBO J 1997; 16: 4797-4805.
• 23 Osterwalder T, Cinelli P, Baici A. et al. The axonally secreted serine proteinase inhibitor, neuroserpin, inhibits plasminogen activators and plasmin but not thrombin. J Biol Chem 1998; 273: 2312-2321.
• 24 Barker-Carlson K, Lawrence DA, Schwartz BS. Acyl-enzyme complexes between tissue type plasminogen activator and neuroserpin are short lived in vitro. J Biol Chem 2002; 277: 46852-7.
• 25 Yepes M, Sandkvist M, Wong MK. et al. Neuroserpin reduces cerebral infarct volume and protects neurons from ischemia-induced apoptosis. Blood 2000; 96: 569-576.
• 26 Nocito A, Kononen J, Kallioniemi OP. et al. Tissue microarrays (TMAs) for high-throughput molecular pathology research. Int J Cancer 2001; 94: 1-5.
• 27 Wu YP, Siao CJ, Lu W. et al. The tissue plasminogen activator (tPA)/plasmin extracellular proteolytic system regulates seizure-induced hippocampal mossy fiber outgrowth through a proteoglycan substrate. J Cell Biol 2000; 148: 1295-1304.
• 28 Endo A, Nagai N, Urano T. et al. Proteolysis of neuronal cell adhesion molecule by the tissue plasminogen activator-plasmin system after kainate injection in the mouse hippocampus. Neurosci Res 1999; 33: 1-8.
• 29 Chen ZL, Strickland S. Neuronal death in the hippocampus is promoted by plasmin-catalyzed degradation of laminin. Cell 1997; 91: 917-925.
• 30 Melchor JP, Pawlak R, Strickland S. The tissue plasminogen activator-plasminogen proteolytic cascade accelerates amyloid-beta (Abeta) degradation and inhibits Abetainduced neurodegeneration. Neurosci 2003; 23: 8867-8871.
• 31 Nicole O, Docagne F, Ali C. et al. The proteolytic activity of tissue-plasminogen activator enhances NMDA receptor-mediated signaling. Nat Med 2001; 07: 59-64.
• 32 Basham ME, Seeds NW. Plasminogen expression in the neonatal and adult mouse brain. J Neurochem 2001; 77: 318-325.
• 33 Parmar PK, Coates LC, Pearson JF. et al. Neuroserpin regulates neurite outgrowth in nerve growth factor-treated PC12 cells. J Neurochem 2002; 82: 1406-1415.
• 34 Belorgey D, Crowther DC, Mahadeva R. et al. Mutant Neuroserpin (S49P) that causes familial encephalopathy with neuroserpin inclusion bodies is a poor proteinase inhibitor and readily forms polymers in vitro. J Biol Chem 2002; 277: 17367-73.
• 35 Gualandris A, Jones TE, Strickland S. et al. Membrane depolarization induces calciumdependent secretion of tissue plasminogen activator. J Neurosci 1996; 16: 2220-2225.
• 36 Makarova A, Mikhailenko I, Bugge TH. et al. The low density lipoprotein receptor-related protein modulates protease activity in the brain by mediating the cellular internalization of both neuroserpin and neuroserpin-tissuetype plasminogen activator complexes. J Biol Chem 2003; 278: 50250-8.